Parabilis Medicines, Inc. (PBLS)
39.11
-0.18
(-0.46%)
USD |
NASDAQ |
Aug 28, 16:00
39.86
+0.75
(+1.92%)
After-Hours: 20:00
Parabilis Medicines Cash from Operations (Quarterly) : -3.622M for June 30, 2026
Cash from Operations (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Cash from Operations (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | -3.622M |
| March 31, 2026 | -49.20M |
| Date | Value |
|---|---|
| June 30, 2025 | -31.09M |
| March 31, 2025 | -34.15M |
Cash From Operations Definition
Represents the net cash flow from the company's business operations.
Cash from Operations (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Cash from Operations (Quarterly) Benchmarks
| Moderna, Inc. | -526.00M |
| Kailera Therapeutics, Inc. | -77.53M |
| Arrowhead Pharmaceuticals, Inc. | -177.47M |
| Oncolytics Biotech, Inc. | -8.066M |
| Sangamo Therapeutics, Inc. | -19.28M |
Cash from Operations (Quarterly) Related Metrics
| Cash from Investing (Quarterly) | -34.06M |
| Cash from Financing (Quarterly) | 795.71M |
| Free Cash Flow | -119.14M |
| Free Cash Flow Per Share (Quarterly) | -0.0343 |
| Free Cash Flow to Equity (Quarterly) | 1.397M |
| Free Cash Flow to Firm (Quarterly) | -4.028M |
| Free Cash Flow Yield | -2.52% |